167 related articles for article (PubMed ID: 32865070)
1. Clinical factors affecting prognosis of limb osteosarcoma in China: a multicenter retrospective analysis.
Han J; Yu Y; Wu S; Wang Z; Zhang W; Zhao M; Yao Y; Hu Y; Wang W; Liu X; Yu W; Cheng J; Yu L; Bao Q; Zhang G; Yu X; Song R
J Int Med Res; 2020 Aug; 48(8):300060520930856. PubMed ID: 32865070
[TBL] [Abstract][Full Text] [Related]
2. Pirarubicin versus doxorubicin in neoadjuvant/adjuvant chemotherapy for stage IIB limb high-grade osteosarcoma: does the analog matter?
Yu W; Tang L; Lin F; Yao Y; Shen Z
Med Oncol; 2015 Jan; 32(1):307. PubMed ID: 25432694
[TBL] [Abstract][Full Text] [Related]
3. IAP Chemotherapy Regimen Is a Viable and Cost-effective Option in Children and Adolescents With Osteosarcoma: A Comparative Analysis With MAP Regimen on Toxicity and Survival.
Verma P; Jain S; Kapoor G; Tripathi R; Sharma P; Doval DC
J Pediatr Hematol Oncol; 2021 May; 43(4):e466-e471. PubMed ID: 32925402
[TBL] [Abstract][Full Text] [Related]
4. Clinical analysis of Chinese limb osteosarcoma patients treated by two combinations of methotrexate, cisplatin, doxorubicin and ifosfamide.
Lin F; Wang Q; Yu W; Tang L; Zheng S; Sun Y; Shen Z; Yao Y; Dong Y
Asia Pac J Clin Oncol; 2011 Sep; 7(3):270-5. PubMed ID: 21884438
[TBL] [Abstract][Full Text] [Related]
5. Carboplatin and doxorubicin in treatment of pediatric osteosarcoma: a 9-year single institute experience in the Northern Region of Thailand.
Choeyprasert W; Natesirinilkul R; Charoenkwan P; Sittipreechacharn S
Asian Pac J Cancer Prev; 2013; 14(2):1101-6. PubMed ID: 23621194
[TBL] [Abstract][Full Text] [Related]
6. Highly effective reduced toxicity dose-intensive pilot protocol for non-metastatic limb osteogenic sarcoma (SCOS 89).
Shkalim-Zemer V; Ash S; Toledano H; Kollender Y; Issakov J; Yaniv I; Cohen IJ
Cancer Chemother Pharmacol; 2015 Nov; 76(5):909-16. PubMed ID: 26365289
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant chemotherapy for pediatric osteosarcoma patients.
Uchida A; Myoui A; Araki N; Yoshikawa H; Shinto Y; Ueda T
Cancer; 1997 Jan; 79(2):411-5. PubMed ID: 9010116
[TBL] [Abstract][Full Text] [Related]
8. Continuous-infusion ifosfamide and doxorubicin combination as second-line chemotherapy for recurrent or refractory osteosarcoma patients in China: a retrospective study.
Huang YJ; He AN; Sun YJ; Shen Z; Min DL; Yao Y
Asian Pac J Cancer Prev; 2015; 16(6):2391-5. PubMed ID: 25824770
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups.
Ferrari S; Smeland S; Mercuri M; Bertoni F; Longhi A; Ruggieri P; Alvegard TA; Picci P; Capanna R; Bernini G; Müller C; Tienghi A; Wiebe T; Comandone A; Böhling T; Del Prever AB; Brosjö O; Bacci G; Saeter G;
J Clin Oncol; 2005 Dec; 23(34):8845-52. PubMed ID: 16246977
[TBL] [Abstract][Full Text] [Related]
10. [Neoadjuvant therapy for localized osteosarcoma of extremities. Results from the Cooperative osteosarcoma study group COSS of 925 patients].
Bielack S; Kempf-Bielack B; Schwenzer D; Birkfellner T; Delling G; Ewerbeck V; Exner GU; Fuchs N; Göbel U; Graf N; Heise U; Helmke K; von Hochstetter AR; Jürgens H; Maas R; Münchow N; Salzer-Kuntschik M; Treuner J; Veltmann U; Werner M; Winkelmann W; Zoubek A; Kotz R
Klin Padiatr; 1999; 211(4):260-70. PubMed ID: 10472560
[TBL] [Abstract][Full Text] [Related]
11. Methotrexate-Etoposide-Ifosfamide Compared with Doxorubicin-Cisplatin-Ifosfamide Chemotherapy in Osteosarcoma Treatment, Patients Aged 18-25 Years.
Marec-Berard P; Laurence V; Occean BV; Ray-Coquard I; Linassier C; Corradini N; Collard O; Chaigneau L; Cupissol D; Kerbrat P; Saada-Bouzid E; Delcambre C; Gouin F; Guillemet C; Jimenez M; Lervat C; Gaspar N; Le Deley MC; Brugieres L; Piperno-Neumann S
J Adolesc Young Adult Oncol; 2020 Apr; 9(2):172-182. PubMed ID: 31702419
[No Abstract] [Full Text] [Related]
12. High-dose methotrexate (HD-MTX) used as an adjunct with other chemotherapeutics for the treatment of osteosarcoma.
Liu Y; Xu Y; Lin N; Jiang S; Wang Y; Ye Z
Cell Biochem Biophys; 2015 Mar; 71(2):1097-104. PubMed ID: 25417058
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant chemotherapy for osteosarcoma of the extremities with metastases at presentation: recent experience at the Rizzoli Institute in 57 patients treated with cisplatin, doxorubicin, and a high dose of methotrexate and ifosfamide.
Bacci G; Briccoli A; Rocca M; Ferrari S; Donati D; Longhi A; Bertoni F; Bacchini P; Giacomini S; Forni C; Manfrini M; Galletti S
Ann Oncol; 2003 Jul; 14(7):1126-34. PubMed ID: 12853357
[TBL] [Abstract][Full Text] [Related]
14. Primary chemotherapy and delayed surgery for nonmetastatic osteosarcoma of the extremities. Results in 164 patients preoperatively treated with high doses of methotrexate followed by cisplatin and doxorubicin.
Bacci G; Picci P; Ferrari S; Ruggieri P; Casadei R; Tienghi A; Brach del Prever A; Gherlinzoni F; Mercuri M; Monti C
Cancer; 1993 Dec; 72(11):3227-38. PubMed ID: 8242546
[TBL] [Abstract][Full Text] [Related]
15. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group.
Meyers PA; Schwartz CL; Krailo MD; Healey JH; Bernstein ML; Betcher D; Ferguson WS; Gebhardt MC; Goorin AM; Harris M; Kleinerman E; Link MP; Nadel H; Nieder M; Siegal GP; Weiner MA; Wells RJ; Womer RB; Grier HE;
J Clin Oncol; 2008 Feb; 26(4):633-8. PubMed ID: 18235123
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant and adjuvant chemotherapy with high-dose ifosfamide, doxorubicin, cisplatin and high-dose methotrexate in non-metastatic osteosarcoma of the extremities: a phase II trial in Japan.
Kudawara I; Aoki Y; Ueda T; Araki N; Naka N; Nakanishi H; Matsumine A; Ieguchi M; Mori S; Myoui A; Kuratsu S; Hashimoto N; Yoshikawa H
J Chemother; 2013 Feb; 25(1):41-8. PubMed ID: 23433444
[TBL] [Abstract][Full Text] [Related]
17. Osteosarcoma recurrences in pediatric patients previously treated with intensive chemotherapy.
Tabone MD; Kalifa C; Rodary C; Raquin M; Valteau-Couanet D; Lemerle J
J Clin Oncol; 1994 Dec; 12(12):2614-20. PubMed ID: 7989936
[TBL] [Abstract][Full Text] [Related]
18. Zoledronate in combination with chemotherapy and surgery to treat osteosarcoma (OS2006): a randomised, multicentre, open-label, phase 3 trial.
Piperno-Neumann S; Le Deley MC; Rédini F; Pacquement H; Marec-Bérard P; Petit P; Brisse H; Lervat C; Gentet JC; Entz-Werlé N; Italiano A; Corradini N; Bompas E; Penel N; Tabone MD; Gomez-Brouchet A; Guinebretière JM; Mascard E; Gouin F; Chevance A; Bonnet N; Blay JY; Brugières L; ; ;
Lancet Oncol; 2016 Aug; 17(8):1070-1080. PubMed ID: 27324280
[TBL] [Abstract][Full Text] [Related]
19. Treatment of large osteosarcoma in children: new approach.
Kobys VL; Konovalenko VF; Repinа NV; Golovko TS; Gulak LO; Tarasova TO; Zaharycheva EV; Matyushok OF
Exp Oncol; 2013 Jun; 35(2):105-8. PubMed ID: 23828385
[TBL] [Abstract][Full Text] [Related]
20. Comparative outcome of Thai pediatric osteosarcoma treated with two protocols: the role of high-dose methotrexate (HDMTX) in a single institute experience.
Choeyprasert W; Pakakasama S; Sirachainan N; Songdej D; Chuansumrit A; Anurathapan U; Hongeng S; Nartthanarung A
Asian Pac J Cancer Prev; 2014; 15(22):9823-9. PubMed ID: 25520112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
